Literature DB >> 8124849

Labetalol and other agents that block both alpha- and beta-adrenergic receptors.

C J Pearce1, J D Wallin.   

Abstract

BACKGROUND: Labetalol, a compound that blocks both alpha- and beta-adrenergic receptors, is the only drug of its class currently available in the United States.
OBJECTIVE: To review the pharmacology of labetalol and related compounds.
SUMMARY: Unlike "pure" beta blockers, labetalol maintains cardiac output, reduces total peripheral resistance, and does not decrease peripheral blood flow. It has been used to treat hypertension of all degrees of severity and may be especially useful in black patients, elderly patients, patients with renal disease, and in pregnancy. It can be used in conditions that produce catecholamine crises, such as pheochromocytoma, clonidine withdrawal, and cocaine overdose. Its hemodynamic profile is attractive for use in myocardial ischemia. The parenteral form is useful in situations where blood pressure must be lowered quickly. The major side effect is orthostatic hypotension, and hepatotoxicity has been reported.
CONCLUSIONS: Labetalol has several advantages over pure beta-blocking drugs and offers an alternative in managing hypertension that is difficult to control.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8124849     DOI: 10.3949/ccjm.61.1.59

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  8 in total

Review 1.  Control of blood pressure in hypertensive neurological emergencies.

Authors:  Lisa Manning; Thompson G Robinson; Craig S Anderson
Journal:  Curr Hypertens Rep       Date:  2014-06       Impact factor: 5.369

Review 2.  Current and future status of beta-blockers in the treatment of hypertension.

Authors:  Steven G Chrysant; George S Chrysant; Billy Dimas
Journal:  Clin Cardiol       Date:  2008-06       Impact factor: 2.882

Review 3.  Anti-hypertensive treatment in pheochromocytoma and paraganglioma: current management and therapeutic features.

Authors:  Alberto Mazza; Michela Armigliato; Maria Cristina Marzola; Laura Schiavon; Domenico Montemurro; Giorgio Vescovo; Marco Zuin; Sotirios Chondrogiannis; Roberta Ravenni; Giuseppe Opocher; Patrick M Colletti; Domenico Rubello
Journal:  Endocrine       Date:  2013-07-02       Impact factor: 3.633

Review 4.  Treatment of acute severe hypertension: current and newer agents.

Authors:  Joseph Varon
Journal:  Drugs       Date:  2008       Impact factor: 9.546

5.  Control of hypertension in the critically ill: a pathophysiological approach.

Authors:  Diamantino Ribeiro Salgado; Eliezer Silva; Jean-Louis Vincent
Journal:  Ann Intensive Care       Date:  2013-06-27       Impact factor: 6.925

6.  Malignant hypertension: does this still exist?

Authors:  Magdalena Domek; Jakub Gumprecht; Gregory Y H Lip; Alena Shantsila
Journal:  J Hum Hypertens       Date:  2019-10-21       Impact factor: 3.012

Review 7.  Perioperative hypertension management.

Authors:  Joseph Varon; Paul E Marik
Journal:  Vasc Health Risk Manag       Date:  2008

Review 8.  Clinical review: the management of hypertensive crises.

Authors:  Joseph Varon; Paul E Marik
Journal:  Crit Care       Date:  2003-07-16       Impact factor: 9.097

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.